Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS 2: Bimatoprost SR in Open-angle Glaucoma or Ocular Hypertension
NCT02250651Phase 3Completed
- Sponsor
- Allergan
- Start
- Dec 2014
- Primary completion
- Oct 2018
- Modality
- Orthosteric Ligands
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Allergan. Primary endpoints: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye at 12 weeks and Intraocular Pressure (IOP) in the Study Eye at 12 weeks. Started Dec 2014; status: completed.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02250651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250651.